Paion AG, which has pursued diversification in its drug development, is now opting for concentration, putting its efforts behind anaesthesia, and the drug candidate, remimazolam, a short-acting sedative that is ready to go into Phase 3 trials.
Paion AG, which has pursued diversification in its drug development, is now opting for concentration, putting its efforts behind anaesthesia, and the drug candidate, remimazolam, a short-acting sedative that is ready to go into Phase 3 trials.